Q1 EPS Estimates for Legend Biotech Reduced by William Blair

Legend Biotech Co. (NASDAQ:LEGN) – Equities researchers at William Blair decreased their Q1 2025 earnings per share (EPS) estimates for shares of Legend Biotech in a research note issued to investors on Wednesday, March 12th. William Blair analyst S. Corwin now anticipates that the company will earn ($0.40) per share for the quarter, down from their prior forecast of ($0.19). The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. William Blair also issued estimates for Legend Biotech’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.33 EPS and FY2026 earnings at $0.79 EPS.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings data on Tuesday, March 11th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.39) by $0.46. The business had revenue of $186.50 million for the quarter, compared to the consensus estimate of $179.00 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm’s revenue was up 134.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.40) EPS.

A number of other equities analysts have also recently issued reports on LEGN. Morgan Stanley lowered their target price on Legend Biotech from $82.00 to $80.00 and set an “overweight” rating for the company in a report on Monday. Piper Sandler restated an “overweight” rating and issued a $78.00 price objective on shares of Legend Biotech in a report on Monday, December 30th. Royal Bank of Canada restated an “outperform” rating and issued a $86.00 price objective on shares of Legend Biotech in a report on Monday, December 9th. HC Wainwright raised their price objective on Legend Biotech from $73.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, March 12th. Finally, Guggenheim restated a “neutral” rating on shares of Legend Biotech in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $79.17.

Legend Biotech Price Performance

LEGN stock opened at $37.94 on Monday. The stock has a 50-day moving average price of $35.75 and a two-hundred day moving average price of $40.61. The stock has a market cap of $6.93 billion, a PE ratio of -39.94 and a beta of 0.19. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. Legend Biotech has a 1 year low of $30.17 and a 1 year high of $65.45.

Institutional Investors Weigh In On Legend Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in LEGN. Signaturefd LLC raised its position in shares of Legend Biotech by 1,052.7% in the fourth quarter. Signaturefd LLC now owns 1,729 shares of the company’s stock valued at $56,000 after buying an additional 1,579 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Legend Biotech in the fourth quarter valued at approximately $56,000. Shell Asset Management Co. raised its position in shares of Legend Biotech by 62.0% in the fourth quarter. Shell Asset Management Co. now owns 2,090 shares of the company’s stock valued at $68,000 after buying an additional 800 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Legend Biotech in the fourth quarter valued at approximately $77,000. Finally, Quadrant Capital Group LLC raised its position in shares of Legend Biotech by 4,296.6% in the fourth quarter. Quadrant Capital Group LLC now owns 3,825 shares of the company’s stock valued at $124,000 after buying an additional 3,738 shares in the last quarter. 70.89% of the stock is currently owned by institutional investors and hedge funds.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).